Beta-Lactam InfusioN Group Study

The George Institute7,203 enrolled

Overview

The purpose of this study is to find out whether continuous infusion of beta-lactam antibiotics or intermittent infusion or beta-lactam antibiotics, offers more health advantages to patients or if there is no difference. The investigators will be looking to see whether patients receiving beta-lactams via one administration method or the other have a better chance of recovering from their illness. They will also be looking at long term outcomes such as quality-of-life and healthcare resource use. Sepsis is caused by toxic substances (toxins) from bacteria and other organism entering the bloodstream from a site of infection. In some people, the infection can progress to sepsis and septic shock where the functions of organs in the body are affected. Patients suffering from sepsis and septic shock are commonly managed in the intensive care unit (ICU) where they are prescribed antibiotics as standard therapy, as well as other therapies to support the functions of the body. Beta-lactam antibiotics are a group of antibiotics commonly used to treat infection in patients with sepsis and septic shock. Currently, beta-lactam antibiotics are most commonly given to patients be intermittent infusions, that is, given at regular intervals throughout 24 hours. New research suggests that giving beta-lactam antibiotics as a continuous infusion may mean that antibiotic concentrations in the blood remain more consistent and may be more effective at killing bacteria. However, the benefit to the patient by giving beta-lactams via continuous infusion has not been tested in a high-quality, large clinical trial.

Aim To conduct a multicentre randomised, controlled trial (RCT) to determine whether continuous infusion of a beta-lactam antibiotic (piperacillin-tazobactam or meropenem) results in decreased all cause Day 90 mortality compared with intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis. Hypothesis The BLING III Study will test the hypothesis that patients managed in the ICU with sepsis, the administration of beta-lactam antibiotics via continuous infusion decreases Day 90 mortality compared with intermittent infusion Design This BLING III study is a prospective, multicentre, open, phase III, RCT. Participants commenced on one of two beta-lactam antibiotics (piperacillin-tazobactam or meropenem) will be randomised to receive the beta-lactam antibiotic via either continuous infusion or intermittent infusion over 30 minutes for the treatment course while in the ICU for up to 90 days after randomisation. For participants where the beta-lactam antibiotic is subsequently changed from piperacillin-tazobactam to meropenem or vice versa for ongoing treatment of the infectious episode, the new prescription will continue to be administered in the allocated method (continuous infusion or intermittent infusion over 30 minutes). Permuted block randomisation with variable block sizes and stratified by site will be conducted via a password-protected, secure web-based interface. The primary endpoint for this trial will be death from all causes at 90 days. 7,000 patients will be enrolled into this study from approximately 70 ICUs worldwide, with approximately 35 ICUs in Australian and New Zealand hospitals. For eligible patients, the administration method of beta-lactam antibiotic, either piperacillin-tazobactam or meropenem, will be randomised to either continuous infusion or intermittent infusion over 30 minutes. The choice of beta-lactam antibiotic and the dose and dosing interval (i.e. the dose the patient will receive in 24 hours) will be determined by the treating physician prior to randomisation. For all patients, data will be collected at baseline and daily whilst in the ICU. Patients will be followed up to day 14, regardless of location in the hospital, to determine test of cure and to identify new acquisition, colonisation or infection with an multi-resistant organism. Additional follow up will occur at 90 days post randomisation.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Documented site of infection or strong suspicion of infection 2. At the time of the assessment of suitability for the study, the treating physician expects the patient will require treatment in the ICU that extends beyond the next calendar day 3. The treating physician has chosen piperacillin-tazobactam or meropenem to treat the episode of infection 4. The treating physician is uncertain if administration of the chosen antibiotic by intermittent or continuous infusion is superior 5. One or more organ dysfunction entry criteria in the previous 24 hours * i. Mean arterial pressure \< 60 mmHg for at least 1 hour * ii. Vasopressors required for \> 4 hours * iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour * iv. Serum creatinine concentration \> 220 µmol/L Exclusion Criteria: 1. Age less than 18 years 2. Receipt of piperacillin-tazobactam or meropenem for more than 24 hours during current infectious episode 3. Patients who are known or suspected to be pregnant 4. Patient has a known allergy to piperacillin-tazobactam or meropenem or penicillin 5. Receiving renal replacement therapy at the time of assessment for eligibility 6. The treating physician is not committed to provision of advanced life-support, including mechanical ventilation, dialysis and vasopressor administration, for at least the next 48 hours 7. Death is deemed imminent and inevitable 8. The patient has previously been enrolled in BLING III

Outcomes

Primary Outcomes

All-cause mortality

Patient mortality status assessed at 90 days after randomisation

Time frame: 90 Days after randomisation

Secondary Outcomes

Clinical Cure

Clinical cure will be defined as the completion of the beta-lactam antibiotic treatment course (on or prior to Day 14) without recommencement of antibiotic therapy within 48 hours of cessation. Participants discharged from hospital within 14 days following randomisation will be considered to meet the definition of clinical cure. Participants who decease while receiving the antibiotic treatment course or where antibiotic therapy is ceased in the setting of death being deemed imminent and inevitable, will be assessed as not meeting the criteria for clinical cure.

Time frame: Day 14 post randomisation

New acquisition, colonisation or infection

New acquisition, colonisation or infection with an Multi-resistant organism (MRO) or Clostridium difficile diarrhoea

Time frame: up to 14 days post randomisation or hospital discharge, whichever is sooner

All cause ICU mortality

Patient mortality status assessed at ICU discharge

Time frame: up to 90 days

All cause hospital mortality

Patient mortality status assessed at hospital discharge